Literature DB >> 33594061

Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum.

Tossapol Pholcharee1, David Oyen1,2, Yevel Flores-Garcia3, Gonzalo Gonzalez-Paez1, Zhen Han1,4, Katherine L Williams5, Wayne Volkmuth5, Daniel Emerling5, Emily Locke6, C Richter King6, Fidel Zavala3, Ian A Wilson7,8.   

Abstract

The most advanced P. falciparum circumsporozoite protein-based malaria vaccine, RTS,S/AS01 (RTS,S), confers partial protection but with antibody titers that wane relatively rapidly, highlighting the need to elicit more potent and durable antibody responses. Here, we elucidate crystal structures, binding affinities and kinetics, and in vivo protection of eight anti-NANP antibodies derived from an RTS,S phase 2a trial and encoded by three different heavy-chain germline genes. The structures reinforce the importance of homotypic Fab-Fab interactions in protective antibodies and the overwhelmingly dominant preference for a germline-encoded aromatic residue for recognition of the NANP motif. In this study, antibody apparent affinity correlates best with protection in an in vivo mouse model, with the more potent antibodies also recognizing epitopes with repeating secondary structural motifs of type I β- and Asn pseudo 310 turns; such insights can be incorporated into design of more effective immunogens and antibodies for passive immunization.

Entities:  

Year:  2021        PMID: 33594061     DOI: 10.1038/s41467-021-21221-4

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  47 in total

1.  Immunization with the RTS,S/AS malaria vaccine induces IFN-γ(+)CD4 T cells that recognize only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge.

Authors:  Robert Schwenk; Joanne M Lumsden; Lisa E Rein; Laure Juompan; Kent E Kester; D Gray Heppner; Urszula Krzych
Journal:  Vaccine       Date:  2011-10-05       Impact factor: 3.641

2.  RTS,S malaria vaccine pilots in three African countries.

Authors:  Paul Adepoju
Journal:  Lancet       Date:  2019-04-27       Impact factor: 79.321

3.  Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria.

Authors:  F Zavala; J P Tam; M R Hollingdale; A H Cochrane; I Quakyi; R S Nussenzweig; V Nussenzweig
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

4.  Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes.

Authors:  R Ménard; A A Sultan; C Cortes; R Altszuler; M R van Dijk; C J Janse; A P Waters; R S Nussenzweig; V Nussenzweig
Journal:  Nature       Date:  1997-01-23       Impact factor: 49.962

5.  A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to hepatocytes.

Authors:  John B Ancsin; Robert Kisilevsky
Journal:  J Biol Chem       Date:  2004-03-07       Impact factor: 5.157

6.  Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells.

Authors:  Alida Coppi; Rita Tewari; Joseph R Bishop; Brandy L Bennett; Roger Lawrence; Jeffrey D Esko; Oliver Billker; Photini Sinnis
Journal:  Cell Host Microbe       Date:  2007-11-15       Impact factor: 21.023

7.  PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data.

Authors:  Amit Bahl; Brian Brunk; Jonathan Crabtree; Martin J Fraunholz; Bindu Gajria; Gregory R Grant; Hagai Ginsburg; Dinesh Gupta; Jessica C Kissinger; Philip Labo; Li Li; Matthew D Mailman; Arthur J Milgram; David S Pearson; David S Roos; Jonathan Schug; Christian J Stoeckert; Patricia Whetzel
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

8.  The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host.

Authors:  Alida Coppi; Ramya Natarajan; Gabriele Pradel; Brandy L Bennett; Eric R James; Mario A Roggero; Giampietro Corradin; Cathrine Persson; Rita Tewari; Photini Sinnis
Journal:  J Exp Med       Date:  2011-01-24       Impact factor: 14.307

9.  Increased pyrethroid resistance in malaria vectors and decreased bed net effectiveness, Burkina Faso.

Authors:  Kobié H Toé; Christopher M Jones; Sagnon N'Fale; Hanafy M Ismail; Roch K Dabiré; Hilary Ranson
Journal:  Emerg Infect Dis       Date:  2014-10       Impact factor: 6.883

10.  Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.

Authors:  William L Hamilton; Roberto Amato; Rob W van der Pluijm; Christopher G Jacob; Huynh Hong Quang; Nguyen Thanh Thuy-Nhien; Tran Tinh Hien; Bouasy Hongvanthong; Keobouphaphone Chindavongsa; Mayfong Mayxay; Rekol Huy; Rithea Leang; Cheah Huch; Lek Dysoley; Chanaki Amaratunga; Seila Suon; Rick M Fairhurst; Rupam Tripura; Thomas J Peto; Yok Sovann; Podjanee Jittamala; Borimas Hanboonkunupakarn; Sasithon Pukrittayakamee; Nguyen Hoang Chau; Mallika Imwong; Mehul Dhorda; Ranitha Vongpromek; Xin Hui S Chan; Richard J Maude; Richard D Pearson; T Nguyen; Kirk Rockett; Eleanor Drury; Sónia Gonçalves; Nicholas J White; Nicholas P Day; Dominic P Kwiatkowski; Arjen M Dondorp; Olivo Miotto
Journal:  Lancet Infect Dis       Date:  2019-07-22       Impact factor: 71.421

View more
  10 in total

1.  The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria.

Authors:  Lawrence T Wang; Nicholas K Hurlburt; Arne Schön; Barbara J Flynn; Yevel Flores-Garcia; Lais S Pereira; Patience K Kiyuka; Marlon Dillon; Brian Bonilla; Fidel Zavala; Azza H Idris; Joseph R Francica; Marie Pancera; Robert A Seder
Journal:  Cell Rep       Date:  2022-02-15       Impact factor: 9.423

2.  Antibody dynamics in children with first or repeat Plasmodium falciparum infections.

Authors:  Eric Rogier; Doug Nace; Pedro R Dimbu; Brian Wakeman; James G Beeson; Chris Drakeley; Kevin Tetteh; Mateusz Plucinski
Journal:  Front Med (Lausanne)       Date:  2022-07-19

Review 3.  RTS,S: the first malaria vaccine.

Authors:  Fidel Zavala
Journal:  J Clin Invest       Date:  2022-01-04       Impact factor: 14.808

Review 4.  How to induce protective humoral immunity against Plasmodium falciparum circumsporozoite protein.

Authors:  Ilka Wahl; Hedda Wardemann
Journal:  J Exp Med       Date:  2022-01-10       Impact factor: 17.579

5.  The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo.

Authors:  Yevel Flores-Garcia; Lawrence T Wang; Minah Park; Beejan Asady; Azza H Idris; Neville K Kisalu; Christian Muñoz; Lais S Pereira; Joseph R Francica; Robert A Seder; Fidel Zavala
Journal:  PLoS Pathog       Date:  2021-11-08       Impact factor: 6.823

6.  Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum.

Authors:  Mark D Langowski; Farhat A Khan; Sofya Savransky; Dallas R Brown; Arasu Balasubramaniyam; William B Harrison; Xiaoyan Zou; Zoltan Beck; Gary R Matyas; Jason A Regules; Robin Miller; Lorraine A Soisson; Adrian H Batchelor; Sheetij Dutta
Journal:  NPJ Vaccines       Date:  2022-01-27       Impact factor: 7.344

7.  Heterotypic interactions drive antibody synergy against a malaria vaccine candidate.

Authors:  Robert J Ragotte; David Pulido; Amelia M Lias; Doris Quinkert; Daniel G W Alanine; Abhishek Jamwal; Hannah Davies; Adéla Nacer; Edward D Lowe; Geoffrey W Grime; Joseph J Illingworth; Robert F Donat; Elspeth F Garman; Paul W Bowyer; Matthew K Higgins; Simon J Draper
Journal:  Nat Commun       Date:  2022-02-17       Impact factor: 17.694

8.  Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats.

Authors:  Iga Kucharska; Lamia Hossain; Danton Ivanochko; Qiren Yang; John L Rubinstein; Régis Pomès; Jean-Philippe Julien
Journal:  Elife       Date:  2022-01-13       Impact factor: 8.140

9.  A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum.

Authors:  Nathan Beutler; Tossapol Pholcharee; David Oyen; Yevel Flores-Garcia; Randall S MacGill; Elijah Garcia; Jaeson Calla; Mara Parren; Linlin Yang; Wayne Volkmuth; Emily Locke; Jason A Regules; Sheetij Dutta; Daniel Emerling; Angela M Early; Daniel E Neafsey; Elizabeth A Winzeler; C Richter King; Fidel Zavala; Dennis R Burton; Ian A Wilson; Thomas F Rogers
Journal:  PLoS Pathog       Date:  2022-03-28       Impact factor: 6.823

10.  Functional human IgA targets a conserved site on malaria sporozoites.

Authors:  Joshua Tan; Hyeseon Cho; Tossapol Pholcharee; Lais S Pereira; Safiatou Doumbo; Didier Doumtabe; Barbara J Flynn; Arne Schön; Sachie Kanatani; Samantha O Aylor; David Oyen; Rachel Vistein; Lawrence Wang; Marlon Dillon; Jeff Skinner; Mary Peterson; Shanping Li; Azza H Idris; Alvaro Molina-Cruz; Ming Zhao; Lisa Renee Olano; Patricia J Lee; Alison Roth; Photini Sinnis; Carolina Barillas-Mury; Kassoum Kayentao; Aissata Ongoiba; Joseph R Francica; Boubacar Traore; Ian A Wilson; Robert A Seder; Peter D Crompton
Journal:  Sci Transl Med       Date:  2021-06-23       Impact factor: 17.956

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.